Risk Factors of Salvage Procedure for Refractory Morcellation During Holmium Laser Enucleation of the Prostate
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to identify the risk factors for salvage procedure (SP) required for refractory adenomatous tissue resistant to morcellation during holmium laser enucleation of the prostate (HoLEP). Methods: Patients who underwent HoLEP between January 2010 and April 2020 at Seoul National University Hospital were analyzed. SPs were defined as cases of conversion to resection of the prostatic tissue using an electrosurgical loop after morcellation or secondary morcellation a few days after surgery or conversion to open cystotomy. Results: Among a total of 2,427 patients, 260 were identified as having SP (SP group) (transurethral resection-nodule [n=250, 96.1%], secondary morcellation a few days after surgery [n=9, 3.5%], and conversion to open cystotomy [n=1, 0.4%]). Patients in the SP group were older and had higher 5-α reductase inhibitors use, higher prostate-specific antigen, larger total prostate volume, and larger transition zone volume (TZV) than those in the non-SP group. In the multivariable logistic regression analysis, only age and TZV were associated with SP. Compared to 40s and 50s, the odds ratios (ORs) were 3.84 in 60s (95% confidence interval [CI] 1.37–10.78, P=0.011), 4.53 in 70s (95% CI, 1.62–12.62, P=0.004), and 6.59 in 80s or older (95% CI, 2.23– 19.46, P=0.001). The ORs of the SP were analyzed per TZV quartile. Compared to TZV ≤ 20.3 mL, the OR was 3.75 in 32.0 mL <TZV ≤50.4 mL (95% CI, 2.00–7.04, P<0.001) and 8.25 in 50.4 mL <TZV (95% CI, 4.06–16.77, P<0.001). Conclusions: The risk of refractory morcellation increased in patients aged >60 years or those with TZV >32 mL. In order to more efficiently remove these resistant adenomas, it is necessary to develop more efficient morcellators in the future.
Abstract
Purpose: We aimed to identify the risk factors for salvage procedure (SP) required for refractory adenomatous tissue resistant to morcellation during holmium laser enucleation of the prostate (HoLEP). Methods: Patients who underwent HoLEP between January 2010 and April 2020 at Seoul National University Hospital were analyzed. SPs were defined as cases of conversion to resection of the prostatic tissue using an electrosurgical loop after morcellation or secondary morcellation a few days after surgery or conversion to open cystotomy. Results: Among a total of 2,427 patients, 260 were identified as having SP (SP group) (transurethral resection-nodule [n=250, 96.1%], secondary morcellation a few days after surgery [n=9, 3.5%], and conversion to open cystotomy [n=1, 0.4%]). Patients in the SP group were older and had higher 5-α reductase inhibitors use, higher prostate-specific antigen, larger total prostate volume, and larger transition zone volume (TZV) than those in the non-SP group. In the multivariable logistic regression analysis, only age and TZV were associated with SP. Compared to 40s and 50s, the odds ratios (ORs) were 3.84 in 60s (95% confidence interval [CI] 1.37–10.78, P=0.011), 4.53 in 70s (95% CI, 1.62–12.62, P=0.004), and 6.59 in 80s or older (95% CI, 2.23– 19.46, P=0.001). The ORs of the SP were analyzed per TZV quartile. Compared to TZV ≤ 20.3 mL, the OR was 3.75 in 32.0 mL <TZV ≤50.4 mL (95% CI, 2.00–7.04, P<0.001) and 8.25 in 50.4 mL <TZV (95% CI, 4.06–16.77, P<0.001). Conclusions: The risk of refractory morcellation increased in patients aged >60 years or those with TZV >32 mL. In order to more efficiently remove these resistant adenomas, it is necessary to develop more efficient morcellators in the future.
참고문헌 (21)
- Elmansy HM, "Holmium laser enucleation of the prostate : long-term durability of clinical outcomes and complication rates during 10 years of followup", J Urol, 186, pp.1972~1976 (2011)
- Kuntz RM, "Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100grams : 5-year follow-up results of a randomised clinical trial", Eur Urol, 53, pp.160~166 (2008)
- 김명, "Efficacy and safety of holmium laser enucleation of the prostate for extremely large prostatic adenoma in patients with benign prostatic hyperplasia", Investigative and Clinical Urology, 56(3), pp.218~226 (2015), 대한비뇨의학회
- 오승준, "Current surgical techniques of enucleation in holmium laser enucleation of the prostate", Investigative and Clinical Urology, 60(5), pp.333~342 (2019), 대한비뇨의학회[DOI]
- Vavassori I, "Three-year outcome following holmium laser enucleation of the prostate combined with mechanical morcellation in 330 consecutive patients", Eur Urol, 53, pp.599~604 (2008)
- Songzhe Piao, "Clinical and Pathological Characteristics of Hard Nodules Resistant to Morcellation During Holmium Laser Enucleation of the Prostate", International Neurourology Journal, 19(2), pp.90~98 (2015), 대한배뇨장애요실금학회
- 김명, "Technical Aspects of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia", Investigative and Clinical Urology, 54(9), pp.570~579 (2013), 대한비뇨의학회
- Gilling PJ, "Holmium laser resection of the prostate : preliminary results of a new method for the treatment of benign prostatic hyperplasia", Urology, 47, pp.48~51 (1996)
- Gilling PJ, "Holmium laser enucleation of the prostate(HoLEP)combined with transurethral tissue morcellation : an update on the early clinical experience", J Endourol, 12, pp.457~459 (1998)
- Fraundorfer MR, "Holmium : YAG laser enucleation of the prostate combined with mechanical morcellation : preliminary results", Eur Urol, 33, pp.69~72 (1998)
- El Tayeb MM, "Wolf Piranha versus Lumenis VersaCut prostate morcellation devices : a prospective randomized trial", J Urol, 195, pp.413~417 (2016)
- El-Hakim A, "Holmium laser enucleation of the prostate can be taught : the first learning experience", BJU Int, 90, pp.863~869 (2002)
- Berry SJ, "The development of human benign prostatic hyperplasia with age", J Urol, 132, pp.474~479 (1984)
- Rhodes T, "Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old", J Urol, 161, pp.1174~1179 (1999)
- Roehrborn CG, "Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia", Urology, 53, pp.581~589 (1999)
- Steers WD, "5alpha-reductase activity in the prostate", Urology, 58(6 Suppl 1), pp.17~24 (2001)
- Glassman DT, "Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia", Prostate, 46, pp.45~51 (2001)
- Kozlowski R, "Chronic ischemia alters prostate structure and reactivity in rabbits", J Urol, 165, pp.1019~1026 (2001)
- Zarifpour M, "Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia", Prostate, 75, pp.233~241 (2015)
- Tarcan T, "Age-related erectile and voiding dysfunction : the role of arterial insufficiency", Br J Urol, 82(Suppl 1), pp.26~33 (1998)
- Ritter M, "Standardized comparison of prostate morcellators using a new ex-vivo model", J Endourol, 26, pp.697~700 (2012)